Polidocanol sclerotherapy for hemangiomas and vascular malformations: an up-to-date advance

doi:10.19438/j.cjoms.2020.01.016

Abstract

Abstract: Hemangiomas and vascular malformations are common diseases with a prevalence about 40%-60% in head and neck, which can cause significant aesthetic and functional problem, even leading to death. The treatment of complex hemangiomas and vascular malformations remain a global challenge. The current treatment strategy mainly include surgical resection, sclerotherapy, laser therapy and endovascular interventional therapy. As an effective method for venous malformations and lymphatic malformations, sclerotherapy has been gradually used in treating hemangiomas and pyogenic granuloma. Polidocanol is one of the sclerosing agents widely used worldwide. This article reviewed the background and up-to-date advances of polidocanol in treating hemangiomas and vascular malformations.

Key words: Polidocanol, Sclerotherapy, Foam scleroagent, Hemangiomas, Vascular malformations

CLC Number:

R739.8

ZHANG Han-shu, LIU Shao-hua, ZHENG Jia-wei. Polidocanol sclerotherapy for hemangiomas and vascular malformations: an up-to-date advance[J]. China Journal of Oral and Maxillofacial Surgery, 2020, 18(1): 77-81.

References

[1] Zheng JW, Zhou Q, Yang XJ, et al.Treatment guideline for hemangiomas and vascular malformations of the head and neck[J]. Head Neck, 2010, 32(8): 1088-1098.
[2] 孙玉环,车宗刚,郑家伟. ISSVA 2018脉管异常新分类[J].中国口腔颌面外科杂志, 2019, 17(1): 21-27.
[3] Jackson IT, Carreño R, Potparic Z, et al.Hemangiomas, vascular malformations, and lymphovenous malformations: classification and methods of treatment[J]. Plast Reconstr Surg, 1993, 91(7): 1216-1230.
[4] Goldman MP, Weiss RA.Sclerotherapy: Treatment of varicose and telangiectatic leg veins[M].6th Ed. Italy: Elsever Inc, 2014: 173-197.
[5] Eckmann DM.Polidocanol for endovenous microfoam sclerosant therapy[J]. Expert Opin Investig Drugs, 2009, 18(12): 1919-1927.
[6] Opinion on polidocanol (Laureth-9) European Commission [EB/OL]. http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_113.pdf. 2007.
[7] Wollmann JC.The history of sclerosing foams[J]. Dermatol Surg, 2004, 30(5): 694-703.
[8] Rabe E, Pannier F.Indications, contraindications and performance: European guidelines for sclerotherapy in chronic venous disorders[J]. Phlebology, 2014, 29(1 suppl): 338-354.
[9] Parsi K.Interaction of detergent sclerosants with cell membranes[J]. Phlebology, 2015, 30(5): 306-315.
[10] Parsi K, Exner T, Connor DE, et al.The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro[J]. Eur J Vasc Endovasc Surg, 2008, 36(2): 216-223.
[11] Coleridge Smith P.Sclerotherapy and foam sclerotherapy for varicose veins[J]. Phlebology 2009, 24(6): 260-269.
[12] 杨耀武, 郑家伟, 孙沫逸, 等. 聚桂醇硬化剂治疗口腔颌面部血管瘤和脉管畸形专家共识[J]. 中国口腔颌面外科杂志, 2018, 16(3): 91-94.
[13] Patel SB, Ostler AE, Dos Santos SJ, et al.The effects of environmental and compositional manipulations on the longevity of Tessari-made foam for sclerotherapy[J]. J Vasc Surg Venous Lymphat Disord, 2015, 3(3): 312-318.
[14] 岳琳琳, 王逸飞, 董建勇, 等. 温度对聚桂醇泡沫稳定性的影响[J]. 中国口腔颌面外科杂志, 2017, 15(3): 198-201.
[15] Chen AW, Liu YR, Li K, et al.An investigation on the influence of hyaluronic acid on polidocanol foam stability[J]. Dermatol Surg, 2015, 42(1): 56-58.
[16] Chen AW, Liu SH, Huang YY, et al.Preliminary experience with more stable polidocanol foam in sclerotherapy of head and neck venous malformations[J]. Dermatol Surg, 2018, 44(11): 1421-1426.
[17] Xu J, Wang YF, Chen AW, et al.A modified Tessari method for producing more foam[J]. Springerplus, 2016, 5: 129.
[18] 周捍东, 林晓曦, 安一峰, 等. 平阳霉素加地塞米松局部注射治疗婴幼儿血管瘤[J]. 中华医学美学美容杂志, 2005, 11(5): 291-293.
[19] 李永利, 赵庆书, 刘孟奇, 等. 一次CT导引下置双针穿刺硬化治疗双肾多发肾囊肿的应用体会[J]. 介入放射学杂志, 2011, 20(6): 474-475.
[20] Alòs J, Carreño P, López JA, et al.Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial[J]. Eur J Vas Endovasc Surg, 2006, 31(1):101-107.
[21] 刘珍银, 夏杰军, 徐文婵. 1%聚多卡醇局部注射治疗普通婴幼儿血管瘤疗效观察[J]. 现代医院, 2017, 17(3): 390-392.
[22] 汪垠, 朱飞, 宁金龙, 等. 1%聚桂醇在面部血管瘤及血管畸形治疗中的应用[J]. 中华整形外科杂志, 2012, 28(6): 428-431.
[23] 杨荣强, 张燕敏, 高群, 等. 1%聚桂醇注射液局部注射治疗小儿体表血管瘤的临床观察[J]. 中华小儿外科杂志, 2011, 32(9): 715-716.
[24] Grover C, Arora P, Kedar A, et al.Combination of oral corticosteroids and polidocanol sclerotherapy in the management of infantile hemangiomas[J]. Dermatol Surg, 2010, 36(12): 2030-2036.
[25] 钟斌, 吴书清, 刘辉. 普萘洛尔口服联合聚桂醇局部注射治疗婴幼儿血管瘤临床观察[J]. 山东医药, 2013, 53(3): 76-78.
[26] 丁语, 陆信武, 郑家伟, 等. 聚多卡醇治疗化脓性肉芽肿11例临床观察[J]. 中国皮肤性病学杂志, 2017, 31(9): 119-120, 123.
[27] Blaise S, Charavin-Cocuzza M, Riom H, et al.Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review[J]. Eur J Vasc Endovasc Surg, 2011, 41(3): 412-417.
[28] Górriz-Gómez E, Vicente-Barrero M, Loras-Caballero ML, et al.Sclerotherapy of face and oral cavity low flow vascular malformations: our experience[J]. Br J Oral Maxillofac Surg, 2014, 52(1): 43-47.
[29] Chen AW, Liu YR, Li K, et al.Efficacy of sclerotherapy with radio-opaque foam guided by digital subtraction angiography for the treatment of complex venous malformations of the head and neck[J]. Br J Oral Maxillofac Surg, 2015, 53(9): 809-813.
[30] Hidefumi M, Hiroyasu F, Takao H, et al.Polidocanol sclerotherapy for painful venous malformations: evaluation of safety and efficacy in pain relief[J]. Eur Radiol, 2009, 19(10): 2474-2480.
[31] Mimura H, Kanazawa S, Yasui K, et al.Percutaneous sclerotherapy for venous malformations using polidocanol under fluoroscopy[J]. Acta Medica Okayama, 2003, 57(5): 227-234.
[32] 杨耀武, 孙沫逸. 面颈部淋巴管畸形的综合治疗[C]. 济南: 头颈肿瘤学术会议暨山东省口腔医学会口腔颌面外科分会学术年会暨山东省口腔颌面外科高层论坛暨山东省口腔医学会口腔颌面一头颈肿瘤分会成立大会, 2017.
[33] 范晶, 王立丹, 黄穗, 等. 聚桂醇泡沫硬化剂治疗儿童头颈部大囊型淋巴管畸形疗效研究[J]. 临床放射学杂志, 2014, 33(9): 1412-1415.
[34] Yamaki T, Sasaki Y, Hasegawa Y, et al.Percutaneous ultrasound-guided sclerotherapy with polidocanol microfoam for lymphatic malformations[J]. J Vasc Surg Venous Lymphat Disord, 2017, 5(5): 707-714.
[35] Kitagawa A, Yamamoto T, Matsunaga N, et al.Polidocanol sclerotherapy combined with transarterial embolization using n-butyl cyanoacrylate for extracranial arteriovenous malformations[J]. Cardiovasc Intervent Radiol, 2018, 41(6): 856-866.
[36] Ergun O, Atli E, Gulek B, et al.Intraarterial polidocanol injection for the treatment of peripheral arteriovenous malformations[J]. Surg Today, 2014, 44(7): 1232-1241.
[37] Katada Y, Ouchi K, Wakita T, et al.Liquid sclerotherapy for posttraumatic arteriovenous fistula of the radialis indicis artery[J]. J Vasc Surg, 2010, 52(5): 1343-1345.
[38] 刘莉, 刘冬晓, 赵吉宏, 等. 聚桂醇联合平阳霉素治疗120例静脉畸形疗效观察[J]. 上海口腔医学, 2016, 25(5): 588-592.
[39] Marrocco-Trischitta MM, Guerrini P, Abeni D, et al.Reversible cardiac arrest after polidocanol sclerotherapy of peripheral venous malformation[J]. Dermatol Surg, 2002, 28(2): 153-155.